Drugs / 131I
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05299437 | May 2021 → Mar 2024 | differentiated thyroid carcinoma | Carlo Chiesa | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01843062 Background | Aug 2013 → May 2018 | differentiated thyroid carcinoma | AstraZeneca | Terminated | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 131-I | “A single oral radioactive iodine dose of 100 mCI(3.7 GBq) 131I (+/-10% at the time of administration)to be administered 30 days after randomization.” NCT01843062 ↗1“124-I blood and lesion dosimetry will be used to optimize the 131-I therapeutic activity.” NCT05299437 ↗ |
| Route | Oral | “A single oral radioactive iodine dose” NCT01843062 ↗ |